Article Text

Download PDFPDF
KITD816V+ systemic mastocytosis associated with KITD816V+ acute erythroid leukaemia: first case report with molecular evidence for same progenitor cell derivation
  1. S A McClintock-Treep1,
  2. H-P Horny2,
  3. K Sotlar3,
  4. M K Foucar1,
  5. K K Reichard1
  1. 1
    Department of Pathology, University of New Mexico, Albuquerque, New Mexico, USA
  2. 2
    Institut für Pathologie, Klinikum Ansbach, Escherichstrasse 6DE-91522 Ansbach, Germany
  3. 3
    Institute of Pathology, University of Munich, Munich, Germany
  1. Correspondence to Dr K K Reichard, Tricore Reference Laboratories, 1001 Woodward Place NE, Albuquerque, New Mexico, USA; kreichard{at}salud.unm.edu

Abstract

A case of systemic mastocytosis associated with a clonal haematological non-mast cell lineage disease (SM-AHNMD), where the associated disease is acute erythroid leukaemia (erythroid/myeloid type), is reported. Interestingly, molecular studies showed the KITD816V+ mutation not only in the mast cells, but also in the myeloid blast population and the leukaemic erythroid cells. As is the case with most erythroid leukaemias, the patient had a very aggressive clinical course and died shortly after diagnosis. It is believed that this is the first reported case of systemic mastocytosis with erythroid leukaemia where the KITD816V+ mutation was detected in all three cell types. Molecular findings provide evidence for derivation of these seemingly morphologically distinct lesions from the same clonal precursor cell. From a practice standpoint, this case illustrates the importance of definitively diagnosing the associated non-mast cell lineage disease due to its prognostic implications.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interests None.

  • Patient consent Patient data have been anonymised as patient is deceased and no relatives are listed.

  • Provenance and peer review Not commissioned; externally peer reviewed.